Assembly Biosciences Inc
assemblybio.comWhat Do They Do?
Develops investigational medicines for patients with serious viral diseases, including herpes, hepatitis, and transplant-related infections.
10-K for FY2025, filed Mar 19, 2026We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives…View ↗
How Do They Make Money?
Gilead pays for collaborative research work; payments follow contract billing schedules, and research-service revenue is earned over time as Assembly performs the work.
8-K, filed Aug 13, 2026 10-K for FY2025, filed Mar 19, 2026Revenue from collaborative research with Gilead was $13.4 million for the three months ended June 30, 2026, compared to $9.6 million for…View ↗
$72.3M
-
10-K for FY2025, filed Mar 19, 2026
$72.3M ↗
Who Are Their Customers?
Gilead collaborates with Assembly on its herpes drug program and licensed the program; Assembly receives revenue from collaborative research with Gilead.
10-K for FY2025, filed Mar 19, 2026 8-K, filed Aug 13, 2026We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives…View ↗
Revenue from collaborative research with Gilead was $13.4 million for the three months ended June 30, 2026, compared to $9.6 million for…View ↗
Do Revenues Turn Into Profits?
No. It lost $6.1M in FY2025.
10-K for FY2025, filed Mar 19, 2026
−$12.1MView ↗
10-K for FY2025, filed Mar 19, 2026
−$6.1MView ↗
10-K for FY2025, filed Mar 19, 2026
−$41.2MView ↗
How Are They Changing?
Growing. Revenue grew 11.6x in 4 years, from $6.3M in FY2021 to $72.3M in FY2025, about 84% a year.
Herpes program licensed to Gilead
The older report described Assembly advancing its herpes candidate toward clinical trials; the latest says Gilead licensed the program and will control later development.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 19, 2026Novel Antivirals Targeting Herpesviruses – Advancing (1) ABI-5366 (5366), a long-acting HSV-2 helicase inhibitor targeting high-recurrence…View ↗
Based on the limitations of current therapies, we see a path to advancing the treatment paradigm for people suffering from recurrent…View ↗
HBV candidate moves toward partnering
The older report described advancing a next-generation HBV core inhibitor in clinical studies; the latest says Assembly is evaluating partnering opportunities for its HBV candidate.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 19, 2026Highly Potent Next-Generation HBV Core Inhibitors – Advancing our novel next-generation CIs in clinical studies, with 4334 (currently…View ↗
HBV – Evaluating partnering opportunities for ABI-4334 (4334), for which we have initiated a structured process to find potential partners…View ↗
Transplant-virus work advances
The older report described a research program for transplant-related herpesviruses; the latest describes a named oral drug candidate in studies intended to support a regulatory filing.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 19, 2026Novel Antivirals Targeting Herpesviruses – Advancing (1) ABI-5366 (5366), a long-acting HSV-2 helicase inhibitor targeting high-recurrence…View ↗
Transplant-Associated Herpesviruses – Advancing ABI-7272 (7272), our oral broad-spectrum NNPI for the treatment of transplant-associated…View ↗
Who Do They Compete With?
Competes with GlaxoSmithKline, Enanta Pharmaceuticals, Arbutus Biopharma, Vir Bio, Mirum Pharmaceuticals, Huahui Health, Aligos Therapeutics, Innovative Molecules, and AiCuris Anti-infective Cures
10-K for FY2025, filed Mar 19, 2026The pharmaceutical and biotechnology industry is very competitive, and the development and commercialization of new drugs is influenced by…View ↗
Loading...
